Pharmacoethnicity of FOLFIRINOX versus gemcitabine plus nab-paclitaxel in metastatic pancreatic cancer: a systematic review and meta-analysis
GastroenterologiaSobre o estudo
- Desenho
- Metanálise
- Nível de evidência
- 1 · Evidência consolidada
- Revista
- Scientific reports
- Publicado em
- 11 out 2021
- Citações
- 0
O resumo deste estudo é do publisher e não tem licença aberta: por isso mostramos aqui só os dados do estudo, e o texto fica na fonte original, nos links abaixo.
O estudo original
Pharmacoethnicity of FOLFIRINOX versus gemcitabine plus nab-paclitaxel in metastatic pancreatic cancer: a systematic review and meta-analysis
Yoon Suk Lee, Jong-Chan Lee, Jae-Hyeong Kim, Jaihwan Kim, Jin-Hyeok Hwang
Descritores MeSH
- Pancreatic Neoplasms
- Ethnicity
- Antineoplastic Combined Chemotherapy Protocols
- Albumins
- Leucovorin
- Deoxycytidine
- Fluorouracil
- Humans
- Neoplasm Metastasis
- Treatment Outcome
Veja também
Estudos relacionados
- Real-world clinical outcomes and economic burden of metastatic pancreatic ductal adenocarcinoma: a systematic review
- Chemotherapy and radiotherapy for advanced pancreatic cancer
- Comparative Outcomes of First-Line Chemotherapy for Metastatic Pancreatic Cancer Among the Regimens Used in Japan: A Systematic Review and Network Meta-analysis
- NALIRIFOX versus nab-paclitaxel and gemcitabine in older patients with treatment-naive metastatic pancreatic cancer: a subgroup analysis of the pivotal NAPOLI 3 trial